Download PDF
Hamostaseologie 2020; 40(05): 655-661
DOI: 10.1055/a-1129-2573
Original Article

Factors Influencing the Choice between DOACs and LMWHs: A Survey of German Physicians on the Treatment of Cancer-Associated Venous Thromboembolism

Axel Matzdorff
1   Department of Internal Medicine II, Asklepios Clinic Uckermark, Schwedt, Germany
,
Florian Langer
2   Department of Internal Medicine II, Hemostasis Clinic and Hemophilia Center, University Medical Center Eppendorf, Hamburg, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Recently direct-acting oral anticoagulants (DOACs) have become a new therapeutic option besides parenteral anticoagulants to treat cancer-associated venous thromboembolism (VTE). With this survey we wanted to identify factors influencing the choice between low-molecular-weight heparin and DOACs among physicians treating cancer patients. A questionnaire was presented at several medical educational activities on cancer care and VTE management between August 2018 and January 2019. One hundred fifteen physicians returned their surveys. The two most compelling arguments pro DOAC were when the patient had no chemotherapy and when he expressed unwillingness to apply injections. The two most important arguments against DOACs were if the patient had problems with taking oral medications or when he had a history of severe bleeding. This survey shows that future studies need to consider many more factors, particularly patient preferences and physician concerns on bleeding risk, to improve their applicability in daily practice.

Keywords

cancer-associated venous thromboembolism - direct oral anticoagulants - low-molecular-weight heparin


Publication History

Received: 16 June 2019

Accepted: 27 January 2020

Article published online:
30 April 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013; 119 (03) 648-655
    CrossrefPubMedGoogle Scholar
  • 2 Paneesha S, McManus A, Arya R. et al; VERITY Investigators. Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb Haemost 2010; 103 (02) 338-343
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017; 117 (01) 57-65
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Mulder FI, Candeloro M, Kamphuisen PW. et al; CAT-Prediction Collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica 2019; 104 (06) 1277-1287
    CrossrefPubMedGoogle Scholar
  • 5 Hull RD, Pineo GF, Brant RF. et al; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119 (12) 1062-1072
    CrossrefPubMedGoogle Scholar
  • 6 Meyer G, Marjanovic Z, Valcke J. et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162 (15) 1729-1735
    CrossrefPubMedGoogle Scholar
  • 7 Lee AY, Levine MN, Baker RI. et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 8 Lee AYY, Kamphuisen PW, Meyer G. et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
    CrossrefPubMedGoogle Scholar
  • 9 Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12 (04) 389-396
    CrossrefPubMedGoogle Scholar
  • 10 NCCN Clinical Practice Guidelines in Oncology. NCCN Guidelines®. Cancer associated venous thromboembolic disease. Version I. 2016 . Accessed February 25, 2020 at: www.nccn.org
    PubMedGoogle Scholar
  • 11 Farge D, Bounameaux H, Brenner B. et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2016; 17 (10) e452-e466
    CrossrefPubMedGoogle Scholar
  • 12 NCCN Clinical Practice Guidelines in Oncology. NCCN Guidelines®. Cancer associated venous thromboembolic disease. Version I. 2017 . Accessed February 25, 2020 at: www.nccn.org
    PubMedGoogle Scholar
  • 13 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 14 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedGoogle Scholar
  • 15 McBane RD, Wysokinski WE, Le-Rademacher J. et al. Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial. Blood 2018; 132 (Suppl. 01) 421
    CrossrefPubMedGoogle Scholar
  • 16 Khorana AA, Yannicelli D, McCrae KR. et al. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?. Thromb Res 2016; 145: 51-53
    CrossrefPubMedGoogle Scholar
  • 17 Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G. Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica 2015; 100 (11) 1486-1492
    CrossrefPubMedGoogle Scholar
  • 18 Cimminiello C, Anderson Jr FA. Physician and patient perceptions of the route of administration of venous thromboembolism prophylaxis: results from an international survey. Thromb Res 2012; 129 (02) 139-145
    CrossrefPubMedGoogle Scholar
  • 19 Farge D, Cajfinger F, Falvo N. et al. Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC). Oncotarget 2018; 9 (43) 26990-26999
    CrossrefPubMedGoogle Scholar
  • 20 Moyer GC, Bannow BS, Thornburg C. et al. Venous thromboembolism: a survey of oral anticoagulant preferences in the treatment of challenging patient populations. Clin Appl Thromb Hemost 2018; 24 (9 Suppl): 209S-216S
    CrossrefPubMedGoogle Scholar
  • 21 Prins MH, Lensing AW, Brighton TA. et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (01) e37-e46
    CrossrefPubMedGoogle Scholar
  • 22 Agnelli G, Buller HR, Cohen A. et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015; 13 (12) 2187-2191
    CrossrefPubMedGoogle Scholar
  • 23 Raskob GE, van Es N, Segers A. et al; Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 2016; 3 (08) e379-e387
    CrossrefPubMedGoogle Scholar
  • 24 Schulman S, Goldhaber SZ, Kearon C. et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114 (01) 150-157
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147 (02) 475-483
    CrossrefPubMedGoogle Scholar
  • 26 Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 2014; 134 (06) 1214-1219
    CrossrefPubMedGoogle Scholar
  • 27 Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136 (03) 582-589
    CrossrefPubMedGoogle Scholar
  • 28 van der Hulle T, den Exter PL, Kooiman J, van der Hoeven JJM, Huisman MV, Klok FA. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 2014; 12 (07) 1116-1120
    CrossrefPubMedGoogle Scholar
  • 29 Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood 2013; 122 (14) 2310-2317
    CrossrefPubMedGoogle Scholar
  • 30 Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 2014; 19 (01) 82-93
    CrossrefPubMedGoogle Scholar
  • 31 Matzdorff A, Schilling H, Ledig B. Treatment of venous thromboembolism in ambulatory cancer patients in Germany: a prospective non-interventional study. Oncol Res Treat 2015; 38 (04) 174-180
    CrossrefPubMedGoogle Scholar
  • 32 Khorana AA, McCrae KR, Milentijevic D. et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Res Pract Thromb Haemost 2017; 1 (01) 14-22
    CrossrefPubMedGoogle Scholar
  • 33 Mahé I, Sterpu R, Bertoletti L. et al; RIETE Investigators. Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices?. PLoS One 2015; 10 (06) e0128741
    CrossrefPubMedGoogle Scholar
  • 34 Mahé I, Puget H, Buzzi JC. et al. Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study. Support Care Cancer 2016; 24 (08) 3369-3377
    CrossrefPubMedGoogle Scholar
  • 35 Mahé I, Chidiac J, Helfer H, Noble S. Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis. J Thromb Haemost 2016; 14 (11) 2107-2113
    CrossrefPubMedGoogle Scholar
  • 36 Wittkowsky AK. Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis. J Thromb Haemost 2006; 4 (09) 2090-2091
    CrossrefPubMedGoogle Scholar
  • 37 Balas EA, Boren SA. Managing clinical knowledge for health care improvement. Yearb Med Inform 2000; 9 (01) 65-70
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Matzdorff A, Ledig B, Stuecker M, Riess H. Practice patterns for prophylaxis and treatment of venous thromboembolism in German cancer patients. Oncol Res Treat 2016; 39 (04) 194-201
    CrossrefPubMedGoogle Scholar